Published in Vaccine Weekly, December 28th, 2005
According to recent research published in the journal Vaccine, "The aim of this experiment was to develop a cytotoxic cancer vaccine (EC 109-DC) prepared by fusions of esophageal carcinoma cells with dendritic cells (DC2) derived from cord blood and to study the biological characteristics and resultant induction of antitumor immunity."
"CD34+ hematopoietic stern cells were isolated from cord blood using a CD34+ progenitor cell isolation kit by magnetic cell sorting system (MACS). CD34+ cells were incubated with rhGM-CSF, rhTNF-alpha...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly